Trimegestone

Overview

Trimegestone, sold under the brand names Ondeva and Totelle among others, is a progestin medication which is used in menopausal hormone therapy and in the prevention of postmenopausal osteoporosis. It was also under development for use in birth control pills to prevent pregnancy, but ultimately was not marketed for this purpose. The medication is available alone or in combination with an estrogen. It is taken by mouth.[1–6] WP

Side effects of trimegestone include headache, breast tenderness, nervousness, abdominal pain, bloating, muscle cramps, nausea, depression, and vaginal bleeding among others. Trimegestone is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It has weak antiandrogenic and antimineralocorticoid activity and no other important hormonal activity.[1][2][7] WP

Trimegestone was first described in 1979 and was introduced for medical use in 2001. It is sometimes described as a "fourth-generation" progestin. The medication is marketed throughout Europe and Latin America. It is not available in the United States or Canada.[5][8–14] WP

Uses, dosage and effects

Medical uses

Trimegestone is used in menopausal hormone therapy in the treatment of menopausal symptoms such as hot flashes and vaginal atrophy and in the prevention of postmenopausal osteoporosis.[3][6][9][15] WP

Available forms

Trimegestone is available both alone (as Ondeva) and in combination with estradiol (as Ginotex, Lovelle, Minique, Totelle), both of which are approved for the treatment of menopausal symptoms and prevention of postmenopausal osteoporosis. Preparations of trimegestone are oral tablets and contain 0.1 to 0.5 mg of the medication.[6][16][17] WP

Risks and side effects

Side effects

The most common side effects of trimegestone alone at dosages of 0.25 to 0.5 mg/day include breast tenderness (40.7–43.0%), abdominal pain (13.9–16.7%), headache (16.0–19.4%), nervousness (12.7–16.0%), bloating (10.3–16.0%), muscle cramps (12.3–13.9%), nausea (4.8–12.3%), and depression (3.0–3.1%). The most common side effects of the combination of 1 mg/day estradiol and 0.125–0.25 mg/day trimegestone include headache (26.4%), breast pain (15–20%), abdominal pain (18%), and vaginal bleeding (9–18%), and metrorrhagia (18.8%).[1][7] WP

Pharmacology

Pharmacodynamics

Trimegestone is a progestogen, or an agonist of the progesterone receptor (PR). It has very high affinity for the PR, about 588 to 660% of that of progesterone. This is greater than that of almost all other widely used progestins, with the exception of the 19-nortestosterone derivative gestodene (which has about 864% of the affinity of progesterone). In accordance with its very high affinity for the PR, trimegestone is described as a very potent progestogen, showing secretory transformation of the estrogen-treated endometrium at a dosage of only 0.1 mg/day, and is the most potent progestin of the 19-norprogesterone group. Like other progestogens, trimegestone has functional antiestrogenic effects in certain tissues such as the endometrium and has antigonadotropic effects. The endometrial transformation dosage of trimegestone is 0.25 to 0.5 mg/day and its ovulation-inhibiting dosage is 0.5 mg/day.[2][15][18–21] WP

In addition to its affinity for the PR, trimegestone has moderate affinity for the mineralocorticoid receptor (42–120% of that of aldosterone), weak to very weak affinity for the glucocorticoid and androgen receptors (9–13% of that of dexamethasone and 1–2.4% of that of testosterone, respectively), and no affinity for the estrogen receptor (less than 0.02% of that of estradiol). In accordance, it possesses weak antimineralocorticoid activity, very weak antiandrogenic activity, and no androgenic, estrogenic, glucocorticoid, antiglucocorticoid, or mineralocorticoid activity. As such, it is a selective and mostly pure progestogen. Unlike progesterone, trimegestone does not metabolize into neurosteroids and hence does not influence GABAA receptor signaling or produce sedative side effects.[1][2][15][18][19] WP

The antiandrogenic potency of trimegestone in animals is about 30% of that of cyproterone acetate.[22] WP

Pharmacokinetics

The oral bioavailability of trimegestone is about 100%. Following a single oral dose of trimegestone, peak serum concentrations occur within 0.5 hours and are 12–15 ng/mL (35–44 nmol/L) for a 0.5 mg dose and 25 ng/mL (73 nmol/L) for a 1 mg dose. Circulating levels of trimegestone increase proportionally across dosages of 0.25 to 1 mg/day. Steady-state levels of trimegestone are achieved within 3 days of daily administration. The plasma protein binding of trimegestone is 98%; it is bound to albumin. Trimegestone is metabolized mainly via hydroxylation. The 1β- and 6β-hydroxy metabolites of trimegestone are progestogens with considerable potency similarly and show little or no affinity to other steroid hormone receptors. The elimination half-life of trimegestone is between 12 and 20 hours, with an average of about 13.8 to 15.6 hours.[1][2][3][21][23] WP

Research

Research

The oral combination of trimegestone and ethinylestradiol was under development by Wyeth in the United States as a birth control pill to prevent pregnancy and the oral combination of trimegestone and conjugated estrogens was under development by Wyeth in the United States to treat menopausal syndrome and to prevent postmenopausal osteoporosis, but the development of both formulations was discontinued and they were never marketed. A transdermal patch with the developmental code name PSK-3987 containing estradiol and trimegestone was under development by ProStrakan for the treatment of menopausal syndrome, but it too never completed development and hence was not marketed.[4][24][25] WP

History

History

Trimegestone was first described in 1979 and was introduced for medical use in 2001. It was discovered as an active metabolite of promegestone. The medication originated by Sanofi-Aventis in France, where promegestone was developed, and was first marketed by Wyeth in Sweden.[8][9][10][20][26][27] WP

Legal status

Generic names

Trimegestone is the generic name of the drug and its INN (International Nonproprietary Name), USAN (United States Adopted Name), and BAN (British Approved Name), while trimégestone is its DCF (Dénomination Commune Française). It is also known by its developmental code name RU-27987.[5][28][29] WP

Brand names

Trimegestone under the brand names Ginotex, Lovelle, Lovelle Ciclico, Lovelle Continuo, Minique, Ondeva, Totelle, Totelle Ciclico, Totelle Ciclo, Totelle Continuo, Totelle Cycle, Totelle Cyclo, Totelle Secuencial, and Totelle Sekvens. With the exception of Ondeva, which is formulated alone, all of these products are formulated in combination with estradiol.[3][5][10][13][29][30] WP

Availability

Trimegestone is or has been marketed in Europe and Latin America, including in Argentina, Austria, Belgium, Brazil, Chile, Denmark, Finland, France, Italy, Lithuania, Mexico, Norway, Sweden, and Venezuela. It is not available in any predominantly English-speaking countries, including the United States, Canada, the United Kingdom, Ireland, Australia, New Zealand, or South Africa.[3][5][13][14][27][29] WP

Chemistry

Formula

C22H30O3 PC

CAS number

74513-62-5 PC

Molar mass (g/mol)

342.5 PC

IUPAC name (computed by PubChem)

(8S,13S,14S,17S)-17-[(2S)-2-hydroxypropanoyl]-13,17-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one PC

SMILES

C[C@@H](C(=O)[C@]1(CC[C@@H]2[C@@]1(CCC3=C4CCC(=O)C=C4CC[C@@H]23)C)C)O PC

InChIKey

JUNDJWOLDSCTFK-MTZCLOFQSA-N PC

PubChem CID

68926

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Sitruk-Ware R, Bossemeyer R, Bouchard P. Preclinical and clinical properties of trimegestone: a potent and selective progestin. Gynecol. Endocrinol. June 2007. doi:10.1080/09513590701267727 · PMID 17616854
2. Journal / agency Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005. doi:10.1080/13697130500148875 · PMID 16112947
3. Journal / agency Stanczyk FZ. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocr Metab Disord. 2002. doi:10.1023/A:1020072325818 · PMID 12215716
4. Journal / agency Ethinylestradiol/trimegestone
5. Other Trimegestone
6. Journal / agency Trimegestone
7. Journal / agency Wahab M, Al-Azzawi F. Trimegestone: expanding therapeutic choices for the treatment of the menopause. Expert Opin Investig Drugs. September 2001. doi:10.1517/13543784.10.9.1737 · PMID 11772282
8. Other Beato M. Steroid Induced Uterine Proteins: Proceedings of the International Symposium on Steroid Induced Uterine Proteins Held in Marburg, West Germany, 28-29 September, 1979. 1 January 1980
9. Other Annual Reports in Medicinal Chemistry. 31 December 2012
10. Other Taylor JB, Triggle DJ. Comprehensive Medicinal Chemistry II: Global perspective. 2007
11. Journal / agency Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging. 2004. doi:10.2165/00002512-200421130-00004 · PMID 15493951
12. Other Briggs P, Kovacs G. Contraception: A Casebook from Menarche to Menopause. 11 July 2013
13. Other Micromedex Products: Please Login
14. Other Lemke TL, Williams DA. Foye's Principles of Medicinal Chemistry. 24 January 2012
15. Other Ottow E, Weinmann H. Nuclear Receptors as Drug Targets. 8 September 2008
16. Journal / agency Estradiol/trimegestone
17. Other Birkhauser M, Barlow D, Notelovitz M, Rees M. Health Plan for the Adult Woman: Management Handbook. 12 August 2005
18. Journal / agency Winneker RC, Bitran D, Zhang Z. The preclinical biology of a new potent and selective progestin: trimegestone. Steroids. 2003. doi:10.1016/s0039-128x(03)00142-9 · PMID 14667983
19. Journal / agency Philibert D, Bouchoux F, Degryse M, Lecaque D, Petit F, Gaillard M. The pharmacological profile of a novel norpregnance progestin (trimegestone). Gynecol. Endocrinol. October 1999. doi:10.3109/09513599909167574 · PMID 10599548
20. Journal / agency Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Classification and pharmacology of progestins. Maturitas. 2008. doi:10.1016/j.maturitas.2008.11.013 · PMID 19434889
21. Journal / agency Kuhl H. Pharmacology of progestogens. Journal für Reproduktionsmedizin und Endokrinologie-Journal of Reproductive Medicine and Endocrinology. 2011
22. Journal / agency Sitruk-Ware R, Husmann F, Thijssen JH, Skouby SO, Fruzzetti F, Hanker J, Huber J, Druckmann R. Role of progestins with partial antiandrogenic effects. Climacteric. September 2004. doi:10.1080/13697130400001307 · PMID 15669548
23. Other Carp HJ. Progestogens in Obstetrics and Gynecology. 9 April 2015
24. Journal / agency Conjugated estrogens/trimegestone - Wyeth
25. Journal / agency Estradiol/trimegestone transdermal patch - ProStrakan
26. Other Litwack G. Biochemical Actions of Hormones. 2 December 2012
27. Other Doherty AM. Annual Reports in Medicinal Chemistry. 2002
28. Other Ganellin CR, Triggle DJ. Dictionary of Pharmacological Agents. 21 November 1996
29. Other Martindale: The Complete Drug Reference. 2009
30. Journal / agency Bernardelli P, Gaudillière B, Vergne F. Annual Reports in Medicinal Chemistry Volume 37. Annual Reports in Medicinal Chemistry. 2002. doi:10.1016/S0065-7743(02)37027-1

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.